Terms: = Prostate cancer AND SUZ12, CHET9, 23512, ENSG00000178691, Q15022, KIAA0160, JJAZ1 AND Prognosis
4 results:
1. PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing.
Fong KW; Zhao JC; Lu X; Kim J; Piunti A; Shilatifard A; Yu J
Mol Cell; 2022 Dec; 82(24):4611-4626.e7. PubMed ID: 36476474
[TBL] [Abstract] [Full Text] [Related]
2. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.
Deb G; Thakur VS; Gupta S
Epigenetics; 2013 May; 8(5):464-76. PubMed ID: 23644490
[TBL] [Abstract] [Full Text] [Related]
3. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
Crea F; Hurt EM; Mathews LA; Cabarcas SM; Sun L; Marquez VE; Danesi R; Farrar WL
Mol Cancer; 2011 Apr; 10():40. PubMed ID: 21501485
[TBL] [Abstract] [Full Text] [Related]
4. Aberrations of EZH2 in cancer.
Chase A; Cross NC
Clin Cancer Res; 2011 May; 17(9):2613-8. PubMed ID: 21367748
[TBL] [Abstract] [Full Text] [Related]
